() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Mindset Pharma, Next Generation Psychedelics

James Lanthier CEO of Mindset Pharma goes into depth explaining the company for us. As next generation psychedelics are their main focus they are looking at advancing their intellectual property. James shares that he believes the greatest value will be found in the market with that focus. Having two patent applications for their IP and more on the way James is optimistic for their new findings and the opportunities that will hold.

As Mindset Pharma is a private company, their story is just beginning and we're happy to share with you all that we are learning from them. Below, you will find time-stamps for a guide to the interview.

(1:01)- Company background and focus
(4:50)- What areas are they currently working on
(9:55)- Clinical trials that are going on that have them excited
(12:40)- Elements of revenue generation
(15:38)- Any IP that's been put through/on the way
(16:40)- Potential investment opportunities
(19:00)- Where to learn more about the company